Articles tagged with Vaccine Development
Researchers found a powerful antioxidant in Deinococcus radiodurans that combines with manganese to protect against radiation damage. The discovery could lead to synthetic antioxidants tailored for human needs, protecting astronauts and preparing for radiation emergencies.
Scientists at The Jackson Laboratory have identified the CAST/EiJ mouse as a highly susceptible model for studying severe COVID-19. This genetically pure background allows researchers to investigate the virus's impact without artificial receptor modifications, mirroring human responses. Initial trials using antiviral treatments show pr...
A novel vaccine design has demonstrated robust immune response and broad neutralization of HCV strains in mouse models. The innovative approach employs epitope-focused immunogens, which could pave the way for an effective HCV vaccine, potentially limiting its global spread.
A team of UCalgary researchers, led by Dr. Anthony Schryvers, has developed a new vaccine to protect cattle from hemorrhagic septicemia, a deadly bacterial disease that destroys livestock and livelihoods. The vaccine is designed with a long-lasting immune response and has been patented.
Researchers have discovered a monoclonal antibody capable of targeting multiple SARS-CoV-2 variants, including recent Omicron strains. K4-66's exceptional ability to adapt to the virus's frequent mutations makes it a promising candidate for vaccine and therapy development.
Researchers at Penn School of Engineering and Applied Science have developed a new method to refine ionizable lipids, key ingredients in lipid nanoparticles. This approach combines precision with rapid output, enabling safer and more effective mRNA vaccines and therapeutics.
Researchers are developing a novel vaccine and exploring the use of bile acids to fight necrotic enteritis, a preventable intestinal disease in poultry that costs the industry up to $6 billion annually. The vaccine, known as MEFA, targets multiple virulence points of the disease-causing pathogen, providing better protection against inf...
Researchers developed an ingestible capsule that releases a burst of drugs into the stomach or other organs, eliminating the need for injections. The capsule uses compressed carbon dioxide or tightly coiled springs to propel liquid drugs out, targeting specific parts of the digestive tract.
Researchers at Scripps Research have analyzed the molecular structure of viral proteins and developed a more stable form to create effective vaccines. The new design may lead to combination vaccines that target both RSV and human metapneumovirus, reducing hospitalizations for vulnerable populations.
Researchers developed a nasal vaccine combining traditional pertussis antigens with an innovative adjuvant called T-vant to boost immune response. The new vaccine was shown to prevent the bacteria's colonization in the respiratory tract, significantly curbing whooping cough spread.
Scientists have developed an experimental vaccine that combines the benefits of both vaccine strategies, using a horsepox virus to confer safety in a single shot. The new vaccine is substantially more attenuated than the vaccinia virus used in existing vaccines, reducing the risk of side effects and triggering systemic infections.
Researchers created tiny lab-grown models of human immune systems to study immune function in cancer and predict disease treatment response. The miniature models support longer cell function, allowing processes like antibody formation to occur similar to the human body.
Researchers at Cleveland Clinic have made significant progress in their novel vaccine aimed at preventing triple-negative breast cancer. The study found that the investigational vaccine was generally well-tolerated and produced an immune response in most patients, with the highest tolerated dose to date identified.
Researchers at Kumamoto University have developed a cutting-edge diagnostic tool, Intelli-OVI, to rapidly identify emerging SARS-CoV-2 variants. This system combines advanced DNA detection technology with computational algorithms to offer a quicker and more cost-effective method of monitoring viral mutations.
Researchers at Argonne National Laboratory have developed an AI-driven protein design framework that uses multimodal data to speed up the design of new proteins. The framework has been selected as a finalist for the prestigious Gordon Bell Prize, recognizing breakthroughs in high-performance computing.
The TEDDY study aims to understand the causes of type 1 diabetes in children, finding a connection between enterovirus infection, autoantibodies, and disease development. Probiotics may also reduce risk in infants at high danger of developing diabetes-related antibodies.
A phase Ib clinical trial has shown that the MVA-MERS-S vaccine candidate is safe and effective in healthy individuals previously infected with SARS-CoV-2. The vaccine was tested in a placebo-controlled study with no serious vaccine-related side effects, indicating promising results.
Researchers at Nagoya University developed an innovative synthesis technology to produce high-purity, fully chemically synthesized mRNA. This breakthrough cuts down the production time and can be used to address concerns about purity and speed in mRNA vaccine development.
A study by Johns Hopkins Medicine found distinct immune 'signatures' in patients who developed adverse events while taking immunotherapy. These signatures, including increases in white blood cells known as Th2 and Th17, predict the development of immune-related adverse events and may be targeted for treatment.
Induced resistance, a plant-based approach, prepares plants to fight pests and disease by activating their immune systems. This holistic strategy combines multiple methods for tailored protection, enhancing abilities beyond just one defense mechanism.
Scientists at St. Jude Children's Research Hospital found that nutrient availability affects T cell development and mitochondrial activity, inhibiting T cell formation in lysosomes. The study highlights the crucial role of organelle signaling, such as mitochondrial and lysosomal function, in shaping tissue immunity.
A new report argues that countries can cut premature mortality in half by 2050 through targeted health investments. By prioritizing the 15 health conditions causing most premature deaths and implementing public subsidies for essential medicines and diagnostics, nations can achieve this goal.
The authors emphasize the importance of increasing vaccination rates to combat decreasing rates globally. They also highlight emerging challenges such as a highly virulent strain of influenza and measles outbreaks, particularly in areas with low vaccination rates.
Scientists at Houston Methodist will focus on developing efficacious vaccines and therapeutic antibodies for viruses in the Nairoviridae, Hantaviridae, and Paramyxoviridae families. The goal is to prepare for potential outbreaks and develop effective medical countermeasures in response to a next pandemic.
Researchers at Houston Methodist are working on a national consortium to develop vaccines against two common and destructive strains of herpesviruses. The project aims to create prophylactic and therapeutic vaccines using a computational toolkit that could transform vaccine development.
Researchers at Karolinska Institutet have identified a new potential risk marker for cardiovascular disease in older women. Low levels of an anti-inflammatory antibody are associated with a higher risk of heart attack and coronary heart disease, independent of other known risk factors.
Researchers at La Jolla Institute for Immunology have developed six lines of humanized mice to study human cases of COVID-19, shedding light on SARS-CoV-2's movement through the body and varying symptoms. The models help understand how different genetic backgrounds influence disease progression.
Researchers have developed an antibody that can identify Campylobacter jejuni and inhibit its growth, reducing pathogenicity. The antibody targets a multiprotein complex essential for the bacteria's energy production, making it a potential target for therapy and vaccination.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Vanderbilt University Medical Center has joined ReVAMPP, a $100 million program to develop vaccines and antibody therapies against emerging viral threats. The center will focus on nine virus groups that pose the greatest risk to human health, including bunyaviruses and picornaviruses.
Researchers at La Jolla Institute for Immunology have captured the first detailed images of the Ebola virus nucleocapsid structure, which is crucial for replicating in host cells. This breakthrough may accelerate the development of universal antivirals that target this viral structure to combat multiple filoviruses.
Scientists at WashU Medicine are developing strategies and tools to produce vaccines and antibody-based therapies for viruses from five understudied families. The effort aims to rapidly respond to potential future pandemics, with funding totaling $90M over three years.
The development of vaccine adjuvants has evolved significantly, shifting from empirical methods to a more structured approach grounded in rational drug design. This new era emphasizes the importance of understanding structural and functional traits of adjuvants.
Researchers from Thomas Jefferson University and the University of Maryland Baltimore developed a promising new vaccine candidate that protects against Lassa fever. The study demonstrated the vaccine effectively prevents severe cases of the disease and death in preclinical animal models, paving the way for research in people.
A new study published in Microorganisms highlights the importance of small molecule drugs that target the unchanging parts of the SARS-CoV-2 virus. The research suggests that these stable targets could provide a consistent and reliable treatment option for COVID-19, even as vaccines are updated to address changing viral strains.
Researchers at the University of Copenhagen have identified the protein complex that enables the hepatitis C virus to infect cells. This discovery is a significant step towards developing a vaccine against the disease, which causes chronic inflammation and 300,000 deaths annually worldwide. The study's results, published in Nature maga...
A new framework from a global team of scientists aims to overcome translational hurdles in nanomedicine development. The DELIVER guidelines provide early-stage recommendations for maximizing clinical translation and enabling the successful development of new nanomedicine treatments.
Researchers developed a monoclonal antibody called SC27 that targets multiple parts of the SARS-CoV-2 spike protein, including conserved sections. The antibody shows promise against various COVID-19 variants and related coronaviruses, potentially benefiting immunocompromised patients
Researchers developed artificial lymphoid organ-chips to recreate human immune system's response to booster vaccines. The technology could potentially be used to evaluate the likely effectiveness of new protein and mRNA-based booster vaccines for COVID-19 and other infectious diseases.
A team of researchers from Osaka University has pinpointed the B cells responsible for boosting COVID-19 immunity after vaccination. They found that activated atypical B cells are the main responders to mRNA vaccines, providing a new way to assess vaccine response and underlying biology.
A global therapeutics development coalition is proposed to invigorate the pipeline and drive advocacy for increased investment. The coalition aims to develop two Phase-2 ready therapeutics for virus families of pandemic potential, with a focus on equitable access.
A subset of CD4 T cells create an anti-inflammatory environment within the lung tissue, protecting against TB reinfection by limiting bacterial growth and disease severity. The discovery complements previous research on protective immune T cells in controlling TB infection, suggesting a potential key to improving existing vaccines.
Researchers in China used a scenario experiment to test messaging strategies on COVID-19 vaccine uptake. The study found that emphasizing personal risk rather than personal gain or community benefits was most effective in persuading people to get vaccinated.
A new universal flu vaccine candidate has shown strong immune response and protection against severe infection in mice. The vaccine, developed using the COBRA methodology, targets multiple strains of influenza viruses, including H1N1, H3N2, and H5N1, which pose a high risk to humans.
The field of cancer immunotherapy is advancing with innovations in precision medicine, including adoptive cell transfer therapy, TCR-engineered T cells, and natural killer cell therapy. Therapeutic vaccines are also being developed to target specific cancer antigens, offering new treatment options for patients.
A new HPV vaccine has been developed that protects against all cancer-causing HPV types and triggers cellular immune responses to eliminate infected cells. The vaccine's thermal stability and affordability make it an ideal solution for increasing vaccination rates in developing countries.
A recent study has confirmed the efficacy and safety of the dengue vaccine TAK-003, which reduces the risk of contracting the disease by over 50%. The vaccine has shown a high safety profile, with more than 90% of adults and children developing antibodies after administration.
A Phase 1 study evaluates an individualized neoantigen therapy, showing it is well-tolerated and boosts immune activity against cancer-causing cells. The therapy induces multiple forms of T cell proliferation and sustained responses in patients with melanoma and lung cancer.
Researchers from POSTECH and KRICT created a 3D artificial lung using bioprinting technology, closely mimicking the human respiratory tract. This model allows for accurate testing of COVID-19 drugs and development of therapeutic treatments, potentially shortening the drug development process to under 5 years.
Researchers at Stanford University developed a nanoparticle platform to make vaccines more effective against various pathogens. The platform allows for the elicitation of different immune responses, enabling the identification of the most effective type of protection.
Researchers at the University of Houston have developed two nasal sprays, NanoSTING and NanoSTING-SN, to prevent respiratory virus transmission. NanoSTING is an immune activator that can protect against multiple viruses, while NanoSTING-SN is a pan-coronavirus vaccine that can prevent transmission to unvaccinated individuals.
A team of researchers from the University of York and Hull York Medical School has developed a new, safe and effective way to infect volunteers with the parasite that causes leishmaniasis, allowing for the testing of vaccines and preventative measures.
Researchers at WashU Medicine developed a nasal COVID-19 vaccine that halted transmission in hamsters, showing promise for controlling respiratory infections. The vaccine targeted the virus's entry points in the nose and mouth, reducing viral replication and preventing spread.
Researchers at La Jolla Institute for Immunology have discovered immune cells, such as tissue resident memory cells, in the upper airway that can fight infections and build long-term immunity. These findings may lead to better vaccines and a deeper understanding of immunity against respiratory pathogens.
A University of Vienna research team has developed a new generation of RNA building blocks for high-density microarrays, significantly reducing production time. This breakthrough enables faster synthesis and analysis of RNA molecules, opening up new opportunities for medical research and non-invasive diagnostics.
A new study on malignant catarrhal fever (MCF) in cattle reveals the mechanisms of AlHV-1 infection and identifies a crucial viral gene involved in disease development. The research provides a promising basis for developing an effective vaccine against this devastating bovine disease.
Researchers have created nanoparticles that can release drugs in multiple stages, allowing for more precise targeting of specific sites in the body. This technology has the potential to enhance the effectiveness of therapeutics and reduce side effects, paving the way for new treatments and improved patient care.
Researchers at George Mason University's Center for Infectious Disease Research have made a breakthrough in finding a functional cure for HIV. Using an HIV-like virus particle called HIV Rev-dependent lentiviral vector, the team was able to reduce viral reservoirs and boost the immune system to produce antiviral neutralizing antibodies.
A new study has found that 90-95% of participants produced strong T-cell responses after exposure to adenoviral vaccines in a lab setting. This unexpected finding may have implications for the effectiveness and safety of future COVID-19 vaccines, as well as other infectious diseases.
Researchers developed a universal influenza vaccine that targets the internal structural proteins of the virus, providing lifetime immunity against evolving viruses. Six out of 11 nonhuman primates inoculated with the vaccine survived exposure to the H5N1 virus, while unvaccinated primates succumbed to the disease.